Vertex Inaxaplin Data Expands AMKD Market and Lifts Maze Outlook
Truist calls Vertex’s Phase 2b inaxaplin data a validation of APOL1 inhibition in AMKD and sees a 100,000+ extra patient opportunity, plus positive readthrough for Maze.
/ 2 items
